C4 Therapeutics
(NASDAQ) CCCC
C4 Therapeutics Financials at a Glance
Market Cap
$256.63M
Revenue (TTM)
$35.95M
Net Income (TTM)
$104.99M
EPS (TTM)
$-1.36
P/E Ratio
-1.94
Dividend
$0.00
Beta (Volatility)
1.95 (High)
Dividend
$0.00
Beta (Volatility)
1.95 (High)
Price
$2.63
Volume
1
Open
$2.41
Price
$2.63
Volume
1
Open
$2.41
Previous Close
$2.63
Daily Range
$2.41 - $2.66
52-Week Range
$1.08 - $3.82
Dividend
$0.00
Beta (Volatility)
1.95 (High)
Price
$2.63
Volume
1
Open
$2.41
Previous Close
$2.63
Daily Range
$2.41 - $2.66
52-Week Range
$1.08 - $3.82
CCCC News
CCCC: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout C4 Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
104
CEO
Andrew J. Hirsch, MBA
Website
www.c4therapeutics.comHeadquarters
Watertown, MA 02472, US
CCCC Financials
Key Financial Metrics (TTM)
Gross Margin
95%
Operating Margin
-3%
Net Income Margin
-3%
Return on Equity
-44%
Return on Capital
-35%
Return on Assets
-29%
Earnings Yield
-51.55%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$256.63M
Shares Outstanding
97.58M
Volume
1
Short Interest
0.00%
Avg. Volume
2.09M
Financials (TTM)
Gross Profit
$27.97M
Operating Income
$104.49M
EBITDA
$102.91M
Operating Cash Flow
$98.69M
Capital Expenditure
$607.00K
Free Cash Flow
$99.30M
Cash & ST Invst.
$248.54M
Total Debt
$59.98M
C4 Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$11.02M
+112.8%
Gross Profit
$9.21M
+170.0%
Gross Margin
83.61%
N/A
Market Cap
$256.63M
N/A
Market Cap/Employee
$2.33M
N/A
Employees
110
N/A
Net Income
$20.49M
+40.7%
EBITDA
$19.94M
+39.0%
Quarterly Fundamentals
Net Cash
$188.56M
+5.3%
Accounts Receivable
$2.40M
-22.6%
Inventory
$0.00
N/A
Long Term Debt
$53.62M
-10.6%
Short Term Debt
$6.37M
+10.3%
Return on Assets
-29.24%
N/A
Return on Invested Capital
-35.34%
N/A
Free Cash Flow
$22.16M
-23.6%
Operating Cash Flow
$22.14M
-23.5%